Afrin, 0.05% spray 15 ml

An alpha-adrenergic stimulant for topical use. It has a vasoconstrictor effect.

Oxymetazoline causes vasoconstriction of the mucous membranes of the nose, sinuses and eustachian tube, which leads to reduction of their edema and release of nasal breathing in allergic and/or infectious inflammatory rhinitis (runny nose).

. Due to the presence of excipients in the composition of the medicine (microcrystalline cellulose and sodium carmellose and povidone-K29-32) Afrin® nasal spray does not leak from the nose and does not run down the throat because after the introduction into the nasal passages the spray becomes more viscous and is held on the nasal mucosa more effectively than the standard water solution.

According to clinical studies, the drug starts to work within 1 minute and the action lasts up to 12 hours.

Indications

Difficulty in nasal breathing due to colds, inflammation of the sinuses, eustachitis, hay fever, allergic rhinitis, congestion and swelling of the conjunctiva.

Pharmacological effect

Alpha adrenergic stimulant for topical use. Has a vasoconstrictor effect.

Oxymetazoline causes vasoconstriction of the mucous membranes of the nose, paranasal sinuses and eustachian tube, which leads to a decrease in their swelling and the release of nasal breathing in allergic and/or infectious-inflammatory rhinitis (runny nose).

Due to the presence of excipients in the composition of the medicinal product (microcrystalline cellulose and sodium carmellose and povidone-K29-32), Afrin® nasal spray does not flow out of the nose and does not flow down the throat, since after administration into the nasal passages the spray becomes more viscous and is retained on the mucous membranes of the nose more effectively than a standard aqueous solution.

According to clinical studies, the drug begins to act within 1 minute and the effect lasts up to 12 hours.

Special instructions

With prolonged use (more than one week), symptoms of nasal congestion may recur.

If you need to continue treatment for more than 5 days, you should consult your doctor.

Avoid contact of the drug with the eyes.

Impact on the ability to drive vehicles and operate machinery

The drug, when used correctly and in recommended doses, does not affect driving or operating machinery,

however, if side effects such as dizziness occur, the patient should refrain from these activities.

Active ingredient

Oxymetazoline

Composition

1 ml contains:

Active ingredient:

oxymetazoline hydrochloride 0.5 mg;

Excipients:

disodium edetate dihydrate – 300 mcg,

sodium hydrogen phosphate – 975 mcg,

sodium dihydrogen phosphate monohydrate – 5.525 mg,

povidone K29-32 – 30 mg,

benzalkonium chloride solution 17% – 1.471 mg,

macrogol 1450 – 50 mg,

benzyl alcohol – 2.5 mg,

microcrystalline cellulose and sodium carmellose (Avicel RC-591) – 30 mg,

lemon flavoring – 1.5 mg,

purified water – q.s. up to 1 ml.

Pregnancy

The safety of the drug in pregnant women and during lactation has not been established, therefore the drug should be prescribed to pregnant or breastfeeding women only if the expected benefit from using the drug for the mother outweighs the potential risk to the fetus or infant.

Contraindications

Hypersensitivity, atrophic rhinitis, simultaneous use of monoamine oxidase inhibitors (including a period of 14 days after their discontinuation), children under 6 years of age.

With caution

Coronary artery disease, arrhythmias, chronic heart failure, severe atherosclerosis, arterial hypertension, hyperthyroidism, thyrotoxicosis, diabetes mellitus, chronic renal failure, angle-closure glaucoma, prostatic hyperplasia with clinical symptoms, pregnancy, lactation.

Side Effects

Local reactions: transient dryness and burning of the nasal mucosa, dry mouth and throat, sneezing.

With long-term use – tachyphylaxis, reactive hyperemia and atrophy of the nasal mucosa.

Benzalkonium chloride, which is part of the drug, can cause local skin reactions.

Systemic reactions: increased blood pressure, increased anxiety, nausea, dizziness, headache, insomnia, palpitations, sleep disturbances.

Interaction

The drug slows down the absorption of local anesthetic drugs and prolongs their duration of action.

Concomitant use with other vasoconstrictor drugs increases the risk of side effects.

With the simultaneous use of MAO inhibitors (including a period of 14 days after their discontinuation), maprotiline and tricyclic antidepressants – an increase in blood pressure.

Overdose

Symptoms: with a significant overdose or accidental ingestion, nausea, vomiting, cyanosis, fever, tachycardia, arrhythmia, increased blood pressure, shortness of breath, mental disorders, central nervous system depression (drowsiness, decreased body temperature, bradycardia, decreased blood pressure, respiratory arrest and coma) are possible.

Treatment: symptomatic; in case of accidental ingestion – gastric lavage, activated charcoal. Vasopressor drugs are contraindicated.

Storage conditions

At a temperature not exceeding 25 °C

Shelf life

2 years

Manufacturer

Delpharm Montreal Inc., Canada